- Specialized Immune Cells Linked to Malaria: Study
- Jay Leno 'Just Fine' After Checking Into Hospital: Report
- FDA Grants Review Extension for New Diabetes Drug
Here are some of the latest health and medical news developments, compiled by editors of HealthDay:
Specialized Immune Cells Linked to Malaria: Study
A specialized type of immune cell that may help explain why malaria kills some people and not others has been identified by Australian researchers.
Their study of 33 malaria-infected adults in Indonesia found high levels of highly suppressive regulatory T-cells in the blood of those with severe malaria but not in those who weren't as sick, the Associated Press reported.
The findings were published in the journal PLoS Pathogens. The next step is to determine whether these immune cells actually cause more severe malaria or are caused by having a severe case of the disease.
"Our results indicate that severe malaria is accompanied by the induction of highly suppressive T-reg cells that can promote parasite growth," said lead researcher Magdalena Plebanski, of Monash University, the AP reported. Vaccine studies should carefully examine whether recipients develop this type of immune reaction, Plebanski suggested.
Jay Leno 'Just Fine' After Checking Into Hospital: Report
"Tonight" show host Jay Leno is reported to being doing well after he checked himself into a hospital with an undisclosed illness, the Associated Press reported.
Leno's publicist, Dick Guttman, said the comedian left his office at NBC's studios about midday Thursday and checked himself into the hospital for observation. Guttman didn't reveal the hospital or what symptoms Leno experienced, but did say the illness was "mild."
The publicist also said Leno kept working after he went to the hospital, writing jokes and making phone calls, the AP reported.
"Jay Leno is doing just fine," NBC spokeswoman Tracy St. Pierre said in a statement. "He was kidding around with the hospital staff and running his monologue jokes by the doctors and the nurses. He's expected back to work on Monday."
FDA Grants Review Extension for New Diabetes Drug
A review of the proposed diabetes drug saxagliptin has been extended from April 30 until July 30 by the U.S. Food and Drug Administration. The companies developing the drug, Bristol-Myers Squibb and AstraZeneca, requested the extension.
Earlier this month, an FDA panel of outside medical experts determined that the drug doesn't carry an excess cardiovascular risk, the Wall Street Journal reported.
Saxagliptin is a type of drug called a DPP-4 inhibitor that's designed to increase levels of so-called incretin hormones in order to help lower blood glucose levels. The only DPP-4 drug currently on the market in the United States is Merck & Co.'s Januvia.
Late last year, the FDA said drug makers would have to conduct more stringent clinical trials for type 2 diabetes drugs in order to better assess the drugs' heart attack and stroke risks, the Journal reported.
Copyright © 2011 HealthDay. All rights reserved.